Pharma Pulse 7/16/24: New Class of Medicine for Pain Relief On The Horizon, Emotional Intelligence Training Sets New Law Enforcement Standard & more

What Sponsors Can Expect From FDA's Diversity Action Plan Guidance

Del Smith, PhD, co-founder & CEO of Acclinate highlights challenges sponsors may face in light of FDA releasing its Diversity Action Plan guidance.

A New Class of Medicine for Pain Relief On The Horizon

Developed by Vertex Pharmaceuticals, suzetrigine is a promising new class of pain medicine that has been gaining attention for its innovative mechanism of action and reported efficacy; suzetrigine might offer hope for those struggling with acute pain issues who want to avoid opioids and NSAIDs.

Universities Don’t Want AI Research to Leave Them Behind

Outspent by Big Tech, some academics are focusing on research that requires less computing power, even as they try to build more of it.

TalentSmartEQ’s Emotional Intelligence Training Sets New Law Enforcement Standard

TalentSmartEQ has implemented a first-ever statewide program, providing emotional intelligence (EQ) training to more than 4,500 West Virginia law enforcement officers. Known as Project EQ, officers develop their emotional intelligence skills to improve community interactions and decision-making under pressure, while fostering a culture of empathy and resilience between police departments and their communities.

Richard Hughes IV on LinkedIn

In my op-ed in Pharmaceutical Executive this morning, I suggest that Congress have the thoughtful, bipartisan pandemic postmortem that has been missing instead of perpetuating misinformation.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs